Health BridgeBio Achieves Key Milestone in Phase 3 Study of Encaleret BridgeBio has announced significant progress in its clinical development of encaleret, a treatment for patients with Autosomal Dominant Hypercalcemia (ADH1). The CALIBRATE study, a... Editorial14 hours ago